Skip to content
Improving corneal permeability of dexamethasone using penetration enhancing agents: first step towards achieving topical drug delivery to the retina​​

Improving corneal permeability of dexamethasone using penetration enhancing agents: first step towards achieving topical drug delivery to the retina​​

To date, ocular injections and implants are the most effective methods for drug delivery to the back of the eye. However, invasive delivery methods also are costly and risky due to possible complications. In this paper, a novel proprietary polyacetylene polymer and two cell penetrating peptides are compared for topical drug delivery to treat retinal diseases.

Learn more Arrow right
ARVO 2024 presentation: Function-Structure Relationship in the Rat Glaucoma Model​​

ARVO 2024 presentation: Function-Structure Relationship in the Rat Glaucoma Model​​

Examining the link between retinal function and structure in ocular hypertension is crucial for glaucoma research. The rat magnetic microbead model, mimicking glaucoma aspects, provides insights into this relationship. The study aims to examine if behavioral, functional, and morphological parameters have correlation in the rat magnetic microbead glaucoma model.​

Learn more Arrow right
ARVO 2024 presentation: Validating injectable anesthesia for the streptozotocin-induced diabetic retinopathy rat model​

ARVO 2024 presentation: Validating injectable anesthesia for the streptozotocin-induced diabetic retinopathy rat model​

Streptozotocin (STZ) induced hyperglycemic rats, commonly used in preclinical diabetic retinopathy (DR) research, have poor response to the most used laboratory rodent anesthesia such as medetomidine/ketamine mixture (MK), and are prone to develop various welfare issues. The purpose of this study was to compare medetomidine/midazolam/butorphanol anesthesia (MMB) to MK in the STZ induced DR rat model to validate injectable anesthesia with less side effects and faster recovery time without compromising the DR development.

Learn more Arrow right
ARVO 2024 presentation: Synthetic Peptide Hydrogel-Based Human In Vitro Corneal Model​

ARVO 2024 presentation: Synthetic Peptide Hydrogel-Based Human In Vitro Corneal Model​

Synthetic peptide hydrogels are promising scaffolds where cornea epithelium and other cell types can be grown into in vitro cultures. The aim of this study was to develop a corneal model employing a peptide hydrogel layer as a mimetic of corneal stroma. The model was used in the assessment of corneal cytotoxicity and penetration properties of prostaglandin analogs that are considered as first-line treatment for glaucoma.

Learn more Arrow right
ARVO 2024 presentation: Neural Network-Based Isolectin B4 Flat-Mount Analysis in a Novel AAV-hVEGF-Induced Diabetic Retinopathy Animal Model​​

ARVO 2024 presentation: Neural Network-Based Isolectin B4 Flat-Mount Analysis in a Novel AAV-hVEGF-Induced Diabetic Retinopathy Animal Model​​

Diabetic retinopathy (DR) is a complex disease displaying diverse vascular-associated complications, including upregulation of vascular endothelial growth factor (VEGF)-A165, enhanced vascular permeability, and retinal angiogenesis. Current animal models do not fully replicate the spectrum of DR pathologies. In this study, we aim to evaluate the efficacy of adeno-associated virus (AAV)-mediated long-term expression of human VEGF to establish angiogenic DR-related phenotypes in Brown Norway rats, as well as validate a novel artificial intelligence (AI) framework for autonomous quantification of retinal angiogenesis in a newly established DR model.​

Learn more Arrow right
1 2
AAALAC accredited company

All our facilities are AAALAC accredited, reflecting our commitment to the highest standards of animal care in research.